MX347805B - Peptidos del factor viii (fviii) para la induccion de tolerancia inmune y para inmunodiagnostico. - Google Patents

Peptidos del factor viii (fviii) para la induccion de tolerancia inmune y para inmunodiagnostico.

Info

Publication number
MX347805B
MX347805B MX2013004753A MX2013004753A MX347805B MX 347805 B MX347805 B MX 347805B MX 2013004753 A MX2013004753 A MX 2013004753A MX 2013004753 A MX2013004753 A MX 2013004753A MX 347805 B MX347805 B MX 347805B
Authority
MX
Mexico
Prior art keywords
immunodiagnostics
fviii
immune tolerance
tolerance induction
peptides
Prior art date
Application number
MX2013004753A
Other languages
English (en)
Other versions
MX2013004753A (es
Inventor
Schwarz Hans-Peter
Nora Steinitz Katharina
Maria Wilhelmina Van Helden Paula
Maria Reipert Birgit
Ehrlich Hartmut
Original Assignee
Baxalta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta Inc filed Critical Baxalta Inc
Publication of MX2013004753A publication Critical patent/MX2013004753A/es
Publication of MX347805B publication Critical patent/MX347805B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)

Abstract

La presente invención se refiere a péptidos que pueden usarse para reducir la respuesta inmune al FVIII o para inducir tolerancia al FVIII humano en pacientes afectados, por ejemplo, por hemofilia A. Los péptidos también pueden usarse con fines de inmunodiagnostico, para detectar células T CD4+ con especificidad por el FVIII y monitorear los pacientes con hemofilia A durante las terapias de remplazo y durante las terapias de inducción de tolerancia inmune.
MX2013004753A 2010-10-27 2011-10-27 Peptidos del factor viii (fviii) para la induccion de tolerancia inmune y para inmunodiagnostico. MX347805B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US40740210P 2010-10-27 2010-10-27
US201161467894P 2011-03-25 2011-03-25
US201161502476P 2011-06-29 2011-06-29
PCT/US2011/058165 WO2012058480A1 (en) 2010-10-27 2011-10-27 Fviii peptides for immune tolerance induction and immunodiagnostics

Publications (2)

Publication Number Publication Date
MX2013004753A MX2013004753A (es) 2013-09-13
MX347805B true MX347805B (es) 2017-05-15

Family

ID=45349271

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013004753A MX347805B (es) 2010-10-27 2011-10-27 Peptidos del factor viii (fviii) para la induccion de tolerancia inmune y para inmunodiagnostico.

Country Status (20)

Country Link
US (3) US8969524B2 (es)
EP (2) EP2632479B1 (es)
JP (2) JP6122780B2 (es)
KR (2) KR102040867B1 (es)
CN (2) CN104926947A (es)
AR (1) AR083586A1 (es)
AU (2) AU2011319747C1 (es)
BR (1) BR112013010362A2 (es)
CA (1) CA2815239C (es)
DK (1) DK2632479T3 (es)
EA (1) EA034494B1 (es)
ES (2) ES2639039T3 (es)
HK (1) HK1215442A1 (es)
MX (1) MX347805B (es)
NZ (2) NZ703514A (es)
PL (2) PL3260132T3 (es)
PT (1) PT2632479T (es)
SG (2) SG10201600656WA (es)
TW (3) TW201708251A (es)
WO (1) WO2012058480A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006063031A2 (en) 2004-12-06 2006-06-15 Haplomics Allelic variants of human factor viii
RS56069B1 (sr) * 2012-11-12 2017-10-31 Apitope Int Nv Faktor viii-izvedenih peptida za upotrebu u lečenju hemofilije a
EP2928303A4 (en) 2012-12-07 2016-07-13 Haplomics Inc FACTOR VIII MUTATION REPAIR AND TOLERANCE INDUCTION
EP2968499A4 (en) * 2013-03-15 2016-11-30 Haplomics Inc COMPOSITIONS AND METHODS FOR INDUCING IMMUNE TOLERANCE IN FACTOR VIII REPLACEMENT THERAPIES IN PATIENTS WITH HEMOPHILIA A
EP3154639B1 (en) * 2014-06-12 2020-09-02 University Of Hawaii Uses of humanized cobra venom factor for reducing or preventing immunogenicity
EP3250605A1 (en) * 2015-01-26 2017-12-06 Cellectis Anti-hsp70 specific chimeric antigen receptors (cars) for cancer immunotherapy
HUE065455T2 (hu) 2016-04-15 2024-05-28 Takeda Pharmaceuticals Co Eljárás és berendezés egy farmakokinetikai gyógyszer adagolási rendjének biztosítására
US10896749B2 (en) 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1495052B9 (en) * 2002-04-18 2009-12-16 MERCK PATENT GmbH Modified factor viii
US7485314B2 (en) * 2002-05-06 2009-02-03 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Induction of antigen specific immunologic tolerance
EP2302393A1 (en) * 2004-05-21 2011-03-30 The Institute for Systems Biology Compositions and methods for quantification of serum glycoproteins
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
EP2522717B1 (en) 2006-01-04 2014-04-02 Baxter International Inc Oligopeptide-free cell culture media
GB0723712D0 (en) 2007-12-04 2008-01-16 Apitope Technology Bristol Ltd Peptides
US7673687B2 (en) 2007-12-05 2010-03-09 Halliburton Energy Services, Inc. Cement compositions comprising crystalline organic materials and methods of using same
DE202007017320U1 (de) 2007-12-07 2008-02-28 Dittmann, Ludwig Vorrichtung zur Raumbeduftung
GB0801513D0 (en) * 2008-01-28 2008-03-05 Circassia Ltd Peptides from factor VIII
WO2009099991A2 (en) 2008-01-31 2009-08-13 The Brigham And Women's Hospital, Inc. Treatment of cancer
NZ593190A (en) 2008-11-07 2013-01-25 Baxter Int Factor viii formulations

Also Published As

Publication number Publication date
EP3260132B1 (en) 2022-02-09
US8969524B2 (en) 2015-03-03
US20120135019A1 (en) 2012-05-31
JP6122780B2 (ja) 2017-04-26
US20150203567A1 (en) 2015-07-23
BR112013010362A2 (pt) 2016-08-02
TW201708251A (zh) 2017-03-01
AU2011319747C1 (en) 2016-07-14
AU2016202155A1 (en) 2016-04-28
ES2912455T3 (es) 2022-05-26
CA2815239C (en) 2019-02-26
WO2012058480A1 (en) 2012-05-03
CN103298482A (zh) 2013-09-11
AR083586A1 (es) 2013-03-06
EP3260132A1 (en) 2017-12-27
EP2632479A1 (en) 2013-09-04
AU2011319747B2 (en) 2016-01-07
DK2632479T3 (en) 2017-08-07
CN104926947A (zh) 2015-09-23
KR102040867B1 (ko) 2019-11-07
CA2815239A1 (en) 2012-05-03
PL3260132T3 (pl) 2022-08-08
CN103298482B (zh) 2015-08-19
TW201231065A (en) 2012-08-01
JP2014505014A (ja) 2014-02-27
US9512198B2 (en) 2016-12-06
TWI580430B (zh) 2017-05-01
US20170267743A1 (en) 2017-09-21
SG10201600656WA (en) 2016-02-26
PL2632479T3 (pl) 2017-09-29
KR102222864B1 (ko) 2021-03-04
KR20130128404A (ko) 2013-11-26
MX2013004753A (es) 2013-09-13
AU2011319747A1 (en) 2013-05-02
NZ703514A (en) 2017-02-24
AU2016202155B2 (en) 2018-02-01
JP2017095463A (ja) 2017-06-01
EA201390617A1 (ru) 2013-10-30
ES2639039T3 (es) 2017-10-25
NZ609474A (en) 2015-06-26
KR20190126189A (ko) 2019-11-08
EA034494B1 (ru) 2020-02-13
PT2632479T (pt) 2017-07-24
EP2632479B1 (en) 2017-06-14
SG189914A1 (en) 2013-06-28
TW201730205A (zh) 2017-09-01
HK1215442A1 (zh) 2016-08-26

Similar Documents

Publication Publication Date Title
MX347805B (es) Peptidos del factor viii (fviii) para la induccion de tolerancia inmune y para inmunodiagnostico.
MX366090B (es) Combinación farmacéutica para usarse en mejorar la tolerancia a la glucosa en pacientes que padecen diabetes de tipo 2.
NZ627078A (en) Methods of reducing immunogenicity against factor viii in individuals undergoing factor viii therapy
TR201903840T4 (tr) İnsan tamamlayıcı C5'e bağlanan polipeptitler.
IN2012DN06309A (es)
EP2819535A4 (en) MEDICAL / DENTAL / UNIVERSAL GLOVES WITH IMPROVED TEMPERATURE RESISTANCE AND ERGONOMETRY
NZ711373A (en) Fragments of p97 and uses thereof
NZ709392A (en) Synergistic bacterial compositions and methods of production and use thereof
MX2015006234A (es) Uso de akkermansia para tratar trastornos metabolicos.
EP2528934A4 (en) AROMATIC-CATIONIC PEPTIDES AND USES THEREOF
IN2014KN02830A (es)
MX2021006111A (es) Composicion farmaceutica que comprende un anticuerpo anti-gm-csf para usarse en el tratamiento de artritis reumatoide.
PL2542200T3 (pl) Nakładka przeznaczona do użytku zwłaszcza w domach opieki i szpitalach
NZ701408A (en) Proteins that bind pi16 and uses thereof
CY1123049T1 (el) Ανασυνδυασμενο μυκοβακτηριο ως εμβολιο για χρηση σε ανθρωπους
EP2528939A4 (en) RECOMBINANT PROTEINS FOR USE IN VACCINES, ANTIBODIES TO THESE PROTEINS, AND DIAGNOSTIC AND THERAPEUTIC PROCEDURES THEREWITH
NZ631639A (en) Methods and compositions for treating and diagnosing acute myocardial infarction
GB201210686D0 (en) V1B receptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin level
GB201118201D0 (en) Novel peptides
EP2930183A4 (en) RECOMBINANT PROTEIN AND USES FOR DIAGNOSIS OF MULTIPLE SCLEROSIS
WO2012009640A3 (en) B cell depletion for central nervous system injuries and methods and uses thereof
MX362664B (es) Antagonistas peptídicos del receptor de vasopresina 2.
EA201992559A1 (ru) Пептиды фактора viii для индукции иммунной толерантности и иммунодиагностики
GB201102090D0 (en) Antigenic polypeptide
MX2019008148A (es) Uso de peptidos glp-1 de accion prolongada.

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: BAXALTA INCORPORATED

FG Grant or registration